Inventor · disambiguated record
James Daniel Osborne
Also filed as: OSBORNE JAMES · OSBORNE JAMES DANIEL
11 granted patents·4 pending applications·33 citations·filing 2013–2024
87Inventor score
Files withASTEX THERAPEUTICS LTD10CANCER RESEARCH TECH LTD2ALMIRALL SA1CANCER RES TECH LTD1GW RES LTD1
Top patents by PatentIndex Score
15 records- 0195US10544132B2Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activityASTEX THERAPEUTICS LTD·Filed 2016·Granted Jan 28, 2020·10 cites·27 claims
- 0292US10981898B2Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activityASTEX THERAPEUTICS LTD·Filed 2019·Granted Apr 20, 2021·4 cites·27 claims
- 0392US10526311B2Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activityASTEX THERAPEUTICS LTD·Filed 2016·Granted Jan 7, 2020·6 cites·25 claims
- 0485US11261171B1Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activityASTEX THERAPEUTICS LTD·Filed 2019·Granted Mar 1, 2022·2 cites·24 claims
- 0584US12077526B2Isoindolinone inhibitors of the MDM2-P53 interaction and process for making themASTEX THERAPEUTICS LTD·Filed 2023·Granted Sep 3, 2024·1 cites·22 claims
- 0683US11787792B25-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2 Pyridyl]Amino]Pyrazine-2-carbonitrile and therapeutic uses thereofCANCER RESEARCH TECH LTD·Filed 2020·Granted Oct 17, 2023·1 cites·21 claims
- 0782US2025092027A1Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activityASTEX THERAPEUTICS LTD·Filed 2024·Application pending·0 cites
- 0881US9663503B25-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereofCANCER RES TECH LTD·Filed 2013·Granted May 30, 2017·5 cites·19 claims
- 0979US11603367B2Isoindolinone inhibitors of the MDM2-P53 interaction and process for making themASTEX THERAPEUTICS LTD·Filed 2018·Granted Mar 14, 2023·2 cites·12 claims
- 1078US10259806B25-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2 pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereofCANCER RESEARCH TECH LTD·Filed 2017·Granted Apr 16, 2019·2 cites·16 claims
- 1170US12071429B2Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activityASTEX THERAPEUTICS LTD·Filed 2021·Granted Aug 27, 2024·0 cites·27 claims
- 1270US2025074900A1Isoindolinone inhibitors of the mdm2-p53 interaction and process for making themASTEX THERAPEUTICS LTD·Filed 2024·Application pending·0 cites
- 1367US2022106287A1Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activityASTEX THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 1454US2024238218A1Resorcinol derivative as a pharmaceutically active compound and method of preparation thereofGW RES LTD·Filed 2022·Application pending·0 cites
- 1533US10214509B2Amino-substituted heterocyclic derivatives as sodium channel inhibitorsALMIRALL SA·Filed 2016·Granted Feb 26, 2019·0 cites·20 claims
Join the waitlist — get patent alerts
Get an alert when James Daniel Osborne files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →